Premium
Flow cytometry used to identify histiocytic sarcoma: A case report
Author(s) -
Wang Huiping,
Zhang Jiakui,
Tao Qianshan,
Bian Hengjuan,
Shen Yuanyuan,
Li Yingwei,
Tao Lili,
Wang Chunhuai,
Wang Yiping,
Zhai Zhimin
Publication year - 2016
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21262
Subject(s) - histiocytic sarcoma , cd68 , cd11c , malignancy , flow cytometry , pathology , immunohistochemistry , histiocyte , cd14 , sarcoma , immunophenotyping , medicine , monocyte , biology , immunology , phenotype , biochemistry , gene
Histiocytic sarcoma (HS) is an extremely rare but aggressive malignancy of hematopoietic origin. The diagnosis of HS mainly relies on pathological morphology and immunohistochemical staining combined with clinical symptoms. However, whether histiocytic sarcoma can be detected using flow cytometry (FCM) is not clear. We report the case of a 61‐year‐old female patient with a group of abnormal cells identified primarily by FCM. Largeabnormal cells ‐CD68 + CD11c + CD14 + HLA‐DR + CD123 + CD45 + presented in upper forward scatter and side scatter, indicating that a malignancy originally derived from monocyte/macrophage could be histocytic sarcoma. This patient with histiocytic sarcoma was finally confirmed with pathology and immunohistochemistry. In conclusion, HS can be detected by assessment of CD68 + CD11c + CD14 + HLA‐DR + CD123 + CD45 + cells using FCM, suggesting that FCM can be an effective tool for early finding of HS. © 2015 International Clinical Cytometry Society